Improving cancer treatment with a new method for targeted radiation therapy
Official title: Radiotheranostic host:guest pretargeting with Pb-203 and Pb-212
Funded at State University New York Stony Brook · NIH-11058408 · Data updated 2026-11-12
This study is exploring a new way to make cancer treatments using special antibodies safer and more effective by better targeting cancer cells while protecting healthy tissues, so patients can have improved treatment experiences.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project start | March 19, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $390,201 |
| NIH project number | 5R37CA282650-02 |
| Project ID | NIH-11058408 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with specific types of cancer who are undergoing or considering targeted radionuclide therapy.
✕Less likely to help
Patients who do not have cancer or those whose cancer is not amenable to targeted radionuclide therapy may not benefit from this research.
What this research studies
This research focuses on developing a novel pretargeting platform that enhances the safety and effectiveness of monoclonal antibody-based radiopharmaceuticals for cancer treatment. By using a combination of curcubit[7]uril 'hosts' and adamantane 'guests', the approach aims to improve the targeting of cancer cells while minimizing radiation exposure to healthy tissues. The study seeks to create a system that is nonimmunogenic and adaptable to various antibodies and radionuclides, potentially leading to better outcomes in precision nuclear medicine.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective cancer therapies that specifically target tumors while reducing harm to surrounding healthy tissues.
How similar studies have gone: While pretargeting strategies have shown some promise in previous studies, this specific approach utilizing curcubit[7]uril and adamantane is novel and has not been extensively tested.
Where this research is happening
-
State University New York Stony Brook
Stony Brook, United States Active
Researchers
- Principal investigator: Houghton, Jacob — State University New York Stony Brook
- Study coordinator: Houghton, Jacob
Related research
Other NIH-funded projects on the same topics.
-
Understanding how oral microbes interact at the single-cell level
Aimed at uncovering how bacteria in the mouth stick together and influence each other, using advanced imaging to reveal functional connections at the microscopic level.
-
Cellular and circuit-level mechanisms of HIV/NRTI-related pain in the context of opioids
This NIH grant explores how HIV medicines (NRTIs) and opioids may combine to cause chronic pain, aiming to help people living with HIV who experience pain.
-
Using a dye to see how kidneys work and how transporters act
A new, simple dye-based test could help doctors measure kidney tubular function and transporter activity more accurately in people with acute kidney problems.
-
Interneuronal aging in trauma-exposed World Trade Center responders
A study in WTC responders with PTSD will look at brain interneuron health using advanced imaging and proteins to understand how PTSD may affect aging brains.
-
Dynamic PTSD-Related Cognitive Risk in Aging WTC Responders
This project follows World Trade Center responders as they age to understand how PTSD symptoms relate to changes in thinking skills over time.
-
How CHIKV viruses adapt to mosquitoes and cause disease in people
This project explores how the chikungunya virus changes to become better at infecting mosquitoes and causing disease in humans, with the goal of understanding how to prevent transmission and illness.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.